18:33 , Oct 19, 2018 |  BC Week In Review  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
14:41 , Oct 15, 2018 |  BC Extra  |  Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy...
16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
22:49 , Jul 23, 2018 |  BC Extra  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
15:40 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

Reviving NK cells

Researchers from the University of Science and Technology of China have identified a key role for TIGIT in NK cell exhaustion that suggests immunotherapies targeting TIGIT may be useful against cancers that have failed to...
18:18 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Immutep reports ORR data for eftilagimod plus Keytruda in Phase I for melanoma

Immutep Ltd. (ASX:IMM; NASDAQ:IMMP) said eftilagimod alpha (IMP321) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to a best overall response rate (ORR) of 61% in 18 previously treated patients with...
22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...